RX-0201
- Generic Name
- RX-0201
A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05267899
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Whittier, California, United States
🇺🇸University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02089334
- Locations
- 🇺🇸
Rexahn Site, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath